Trial Profile
A Phase 3 Study of SNX-5422 in Patients Neuroendocrine tumors (NETs)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs SNX 5422 (Primary)
- Indications Neuroendocrine tumours
- Focus Registrational; Therapeutic Use
- Sponsors Esanex
- 15 Oct 2018 New trial record
- 04 Oct 2018 According to an Esanex media release, he company has successfully completed the End-of-Phase 2 discussions with the FDA, that have outlined a clinical path toward registration for SNX-5422 in neuroendocrine tumors (NETs). Agreement was reached on trial design, endpoints and statistical control methods.